Nazim Demircan, Associate Professor of Medical Oncology at Marmara university, shared a post on LinkedIn:
“An Encouraging Step Forward in Osteosarcoma
Osteosarcoma has seen limited progress in systemic treatment for decades.
At the ESMO 2026 Presidential Symposium, the phase III ARTEMIS-011 trial demonstrated a substantial improvement in progression-free survival with the B7-H3-directed ADC risvutatug rezetecan (Ris-Rez) versus gemcitabine plus docetaxel in relapsed/refractory osteosarcoma.
Median PFS: 5.5 vs 1.4 months
HR 0.33 (95% CI 0.20–0.55); p<0.0001
Key Takeaway
A potentially important advance in a disease with substantial unmet need. Mature overall survival data and careful assessment of toxicity will be essential.”
You can also read: ARTEMIS-011 at ESMO 2026: Risvutatug Rezetecan Significantly Improves PFS in Relapsed or Refractory Osteosarcoma
